Common Contracts
4 similar null contracts by Artiva Biotherapeutics, Inc.
Re: Employment Offer LetterArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
On behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).
Re: Employment Offer LetterArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, September 16th, 2020.
Re: Employment Offer LetterArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be August 19th, 2019. This offer is contingent upon references and Board approval.
March 16th, 2019 Dr. Peter Flynn Re: Employment Offer Letter Dear PeterArtiva Biotherapeutics, Inc. • April 8th, 2021 • Biological products, (no disgnostic substances)
On behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be April 15th, 2019 (the first date of your employment, the “Start Date”). This offer is contingent upon approval by the Company’s Board of Directors (the “Board”), and your successful completion of a background check to the satisfaction of the Company.
